Biopharma industry leaders say the science to transform medicine manufacturing already exists—what's missing is the operational speed to scale it.

What happened: The 2026 Danaher Summit brought together speakers and panelists from bioprocessing, biopharma and life sciences to discuss how automation, AI, and digital tools are enabling a shift from large-batch production to small-batch and patient-specific manufacturing. Key themes included the role of digital twins (predictive models powered by integrated data) in reducing risk, the necessity of cross-ecosystem collaboration among academia, industry, and regulators, and the integration of sustainability standards into supplier procurement as a core business requirement.

Why it matters: The traditional regulatory and manufacturing playbook no longer fits the complexity of modern therapies, especially personalized and gene therapies. Participants noted that regulators want to move faster and that early alignment between developers, manufacturers, and regulators is reducing friction. For rare diseases, which collectively affect an estimated 300 million people worldwide, tailored regulatory pathways are becoming essential. The bottleneck is not scientific capability but organizational will to operationalize these tools at speed.

What to watch: The organizations that successfully close the gap between technological capability and operational execution will define medicine manufacturing for the next decade. The Summit's consistent finding was that the most progress comes from treating collaboration as a core capability—wiring transparency, shared incentives, and data-driven partnership into how the ecosystem works, not as an add-on.